{"product_id":"handbook-of-dermatology-9781118408544","title":"Handbook of Dermatology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThe\u003ci\u003e Handbook of Dermatology\u003c\/i\u003e consolidates the essential information required for best-practice patient care into one pocket-sized volume. This indispensable reference guide enables practicing and prospective dermatologists to easily look up information on a wide range of dermatological diseases and quickly access the algorithms, protocols, guidelines, and staging and scoring systems that are vital to both clinical practice and exam success. Written and edited by former residents and attending physicians, the \u003ci\u003eHandbook\u003c\/i\u003e contains up-to-date information on general dermatology, surgery, and therapeutics.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface xv\u003c\/p\u003e \u003cp\u003eAcknowledgments xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 General Dermatology 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCommon Work-Ups, Signs, and Management 3\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDermatologic Differential Algorithm 3\u003c\/p\u003e \u003cp\u003eDirect Immunofluorescence (Dif) 3\u003c\/p\u003e \u003cp\u003eFalse positive\/negative DIFs 3\u003c\/p\u003e \u003cp\u003eWorkup Quick Reference Orders 4\u003c\/p\u003e \u003cp\u003eAcne 6\u003c\/p\u003e \u003cp\u003eAlopecia Workup 7\u003c\/p\u003e \u003cp\u003eTelogen effluvium 10\u003c\/p\u003e \u003cp\u003eAndrogenic alopecia 10\u003c\/p\u003e \u003cp\u003eAlopecia areata 11\u003c\/p\u003e \u003cp\u003eOther alopecia treatments 12\u003c\/p\u003e \u003cp\u003eAphthosis Workup and Treatment 13\u003c\/p\u003e \u003cp\u003eDermatologic Signs 15\u003c\/p\u003e \u003cp\u003eFolliculitis 21\u003c\/p\u003e \u003cp\u003eMelasma 22\u003c\/p\u003e \u003cp\u003e\u003cb\u003eImmunology and Immunologic Disease 24\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eLupus Erythematosus 24\u003c\/p\u003e \u003cp\u003eAutoantibody 26\u003c\/p\u003e \u003cp\u003eSensitivities and specificities 26\u003c\/p\u003e \u003cp\u003eIn connective tissue diseases 28\u003c\/p\u003e \u003cp\u003eAnti‐nuclear antibodies 29\u003c\/p\u003e \u003cp\u003eANCA (Anti‐neutrophil cytoplasmic antibodies) 30\u003c\/p\u003e \u003cp\u003eTreatment of ANCA‐associated vasculitis 30\u003c\/p\u003e \u003cp\u003eVasculitis 31\u003c\/p\u003e \u003cp\u003eSmall vessel vasculitis 31\u003c\/p\u003e \u003cp\u003eMedium vessel vasculitis 33\u003c\/p\u003e \u003cp\u003eLarge vessel vasculitis 34\u003c\/p\u003e \u003cp\u003eCryoglobulinemia 34\u003c\/p\u003e \u003cp\u003eBullous Disorders 36\u003c\/p\u003e \u003cp\u003eIntracorneal\/subcorneal 36\u003c\/p\u003e \u003cp\u003eIntraepidermal 36\u003c\/p\u003e \u003cp\u003eSuprabasilar 37\u003c\/p\u003e \u003cp\u003eSubepidermal with little inflammation 37\u003c\/p\u003e \u003cp\u003eEpidermolysis bullosa 39\u003c\/p\u003e \u003cp\u003eMajor bullous diseases – clinicopathologic findings 42\u003c\/p\u003e \u003cp\u003eComplement 46\u003c\/p\u003e \u003cp\u003eAngioedema and complement levels 46\u003c\/p\u003e \u003cp\u003eComplement deficiencies 47\u003c\/p\u003e \u003cp\u003eGVHD 47\u003c\/p\u003e \u003cp\u003eHLA associations 48\u003c\/p\u003e \u003cp\u003eTh profiles 50\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSpecial Sites: Glands, Nail, Bone, Mucosa 51\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGlands 51\u003c\/p\u003e \u003cp\u003eNail terminology 53\u003c\/p\u003e \u003cp\u003eDisorders or drugs associated with nail, Bone, or ocular findings 57\u003c\/p\u003e \u003cp\u003eGenital ulcers 67\u003c\/p\u003e \u003cp\u003e\u003cb\u003eInfection and Infestations 68\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFungal Disease \/ Mycoses 68\u003c\/p\u003e \u003cp\u003eLaboratory tests 68\u003c\/p\u003e \u003cp\u003eSuperficial mycoses 68\u003c\/p\u003e \u003cp\u003eCutaneous mycoses 69\u003c\/p\u003e \u003cp\u003eSubcutaneous mycoses 71\u003c\/p\u003e \u003cp\u003eSystemic mycoses 73\u003c\/p\u003e \u003cp\u003eOpportunistic mycoses 75\u003c\/p\u003e \u003cp\u003eViruses and diseases 78\u003c\/p\u003e \u003cp\u003eHuman papilloma virus 79\u003c\/p\u003e \u003cp\u003eOther viral diseases 80\u003c\/p\u003e \u003cp\u003eInfections\/Bugs 83\u003c\/p\u003e \u003cp\u003eVector‐borne diseases 83\u003c\/p\u003e \u003cp\u003eCreatures in dermatology 88\u003c\/p\u003e \u003cp\u003e\u003cb\u003eContact and Plant Dermatitis 93\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePatch testing 93\u003c\/p\u003e \u003cp\u003eCommon contact allergens 95\u003c\/p\u003e \u003cp\u003eAllergic vs. irritant contact dermatitis 104\u003c\/p\u003e \u003cp\u003eAllergens – location specific 105\u003c\/p\u003e \u003cp\u003eFeatures suggestive of specific irritant\/toxin 106\u003c\/p\u003e \u003cp\u003ePlants and Dermatoses 106\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTumors and Infiltrates 109\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCutaneous T Cell Lyphoma 109\u003c\/p\u003e \u003cp\u003eCutaneous B‐cell lymphoma 113\u003c\/p\u003e \u003cp\u003eLeukemia cutis 113\u003c\/p\u003e \u003cp\u003eMonoclonal Gammopathies in Dermatology 114\u003c\/p\u003e \u003cp\u003eTumors and gene associations 115\u003c\/p\u003e \u003cp\u003e\u003ci\u003eFor Melanoma, BCC, and SCC, see Skin Cancer\u003c\/i\u003e 221\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSystemic and Metabolic Diseases 117\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAmyloidoses 117\u003c\/p\u003e \u003cp\u003eHistiocytosis 119\u003c\/p\u003e \u003cp\u003eXanthomas 124\u003c\/p\u003e \u003cp\u003eHyperlipoproteinemias 125\u003c\/p\u003e \u003cp\u003eVitamin Deficiencies\/Hypervitaminoses 127\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePediatric and Pregnancy Dermatology 131\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eVascular tumors and malformation 131\u003c\/p\u003e \u003cp\u003eInfantile Hemangioma (IH) Management 132\u003c\/p\u003e \u003cp\u003eNeonatal vesiculopustular eruptions 137\u003c\/p\u003e \u003cp\u003eGenodermatoses 142\u003c\/p\u003e \u003cp\u003eChromosome abnormalities 171\u003c\/p\u003e \u003cp\u003eDisorders of cornification 171\u003c\/p\u003e \u003cp\u003eDisorders of connective tissue 175\u003c\/p\u003e \u003cp\u003eEhlers–Danlos 177\u003c\/p\u003e \u003cp\u003eCollagen types 178\u003c\/p\u003e \u003cp\u003eDisorder of hair, Nail, ectoderm 179\u003c\/p\u003e \u003cp\u003eTumor syndromes 185\u003c\/p\u003e \u003cp\u003eDisorders of vascularization 186\u003c\/p\u003e \u003cp\u003eDisorders of metabolism 189\u003c\/p\u003e \u003cp\u003ePorphyrias 191\u003c\/p\u003e \u003cp\u003eDisorders of pigmentation 193\u003c\/p\u003e \u003cp\u003eImmunodeficiency syndromes 196\u003c\/p\u003e \u003cp\u003eMiscellaneous 198\u003c\/p\u003e \u003cp\u003eDermatoses of pregnancy 200\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDermoscopy and Dermatopathology 202\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDermoscopy 202\u003c\/p\u003e \u003cp\u003eDermatopathology 206\u003c\/p\u003e \u003cp\u003eHistochemical staining 206\u003c\/p\u003e \u003cp\u003eImmunohistochemical staining 207\u003c\/p\u003e \u003cp\u003ePathologic bodies 210\u003c\/p\u003e \u003cp\u003eCysts 214\u003c\/p\u003e \u003cp\u003eOther derm path buzzwords, Patterns, DDx 215\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Surgical and Cosmetic Dermatology 219\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSurgical Dermatology 221\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSkin cancer 221\u003c\/p\u003e \u003cp\u003eSurgical margin guidelines 221\u003c\/p\u003e \u003cp\u003eIndication for Mohs micrographic surgery 222\u003c\/p\u003e \u003cp\u003eMelanoma 223\u003c\/p\u003e \u003cp\u003eSquamous cell carcinoma (SCC) 228\u003c\/p\u003e \u003cp\u003eProphylactic antibiotics and antivirals 230\u003c\/p\u003e \u003cp\u003eGuideline for Prophylactic antibiotics 230\u003c\/p\u003e \u003cp\u003eAlgorithm for antibiotic prophylaxis 231\u003c\/p\u003e \u003cp\u003eGuideline for prophylactic antivirals 231\u003c\/p\u003e \u003cp\u003eAntiseptic scrubs 232\u003c\/p\u003e \u003cp\u003eAnesthetics 234\u003c\/p\u003e \u003cp\u003eDose calculation 234\u003c\/p\u003e \u003cp\u003eStandard formula for buffered Lidocaine 234\u003c\/p\u003e \u003cp\u003eTumescent anesthesia 234\u003c\/p\u003e \u003cp\u003eTopical anesthetic (see drug section pg. 316) 235\u003c\/p\u003e \u003cp\u003eAdverse reaction to local anesthetics 235\u003c\/p\u003e \u003cp\u003eLocal anesthetic 236\u003c\/p\u003e \u003cp\u003eNerve blocks 237\u003c\/p\u003e \u003cp\u003eSurgical anatomy 237\u003c\/p\u003e \u003cp\u003eAnatomy of the face 237\u003c\/p\u003e \u003cp\u003eDanger zones in surgery 242\u003c\/p\u003e \u003cp\u003eDermatomal distribution of sensory nerves 244\u003c\/p\u003e \u003cp\u003eAnatomy of the lower extremity venous system 245\u003c\/p\u003e \u003cp\u003eAnatomy of the nail 246\u003c\/p\u003e \u003cp\u003eCutaneous reconstruction 247\u003c\/p\u003e \u003cp\u003eUndermining depths in reconstruction 248\u003c\/p\u003e \u003cp\u003eReconstruction algorithm: STAIRS 248\u003c\/p\u003e \u003cp\u003eSutures 260\u003c\/p\u003e \u003cp\u003eAbsorbable 260\u003c\/p\u003e \u003cp\u003eNonabsorbable 261\u003c\/p\u003e \u003cp\u003eSuture removal time 262\u003c\/p\u003e \u003cp\u003eElectrosurgery 262\u003c\/p\u003e \u003cp\u003eWound healing 262\u003c\/p\u003e \u003cp\u003eWound dressing 263\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCosmetic Dermatology 264\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eLaser 264\u003c\/p\u003e \u003cp\u003eLaser fundamentals 264\u003c\/p\u003e \u003cp\u003eLaser treatment of tattoo pigment 266\u003c\/p\u003e \u003cp\u003ePhotoinduced eye injury 267\u003c\/p\u003e \u003cp\u003eLaser wavelength depth of penetration and the electromagnetic spectrum 268\u003c\/p\u003e \u003cp\u003eAbsorption spectra of major skin chromophores 268\u003c\/p\u003e \u003cp\u003ePhotodynamic therapy 269\u003c\/p\u003e \u003cp\u003ePhotosensitizer properties and options 269\u003c\/p\u003e \u003cp\u003ePDT Protocol 270\u003c\/p\u003e \u003cp\u003eUV spectrum 271\u003c\/p\u003e \u003cp\u003eUV spectrum and wavelengths 271\u003c\/p\u003e \u003cp\u003eUVB protection vs SPF 272\u003c\/p\u003e \u003cp\u003eUV protection measurements 272\u003c\/p\u003e \u003cp\u003eUV associations\/specificities 273\u003c\/p\u003e \u003cp\u003eGlogau wrinkle scale 273\u003c\/p\u003e \u003cp\u003eFitzpatrick skin type 274\u003c\/p\u003e \u003cp\u003eChemical peels 274\u003c\/p\u003e \u003cp\u003ePre‐peel consideration 274\u003c\/p\u003e \u003cp\u003ePeeling agents 275\u003c\/p\u003e \u003cp\u003eBotulinum toxin 277\u003c\/p\u003e \u003cp\u003eInjectable for adipolysis 280\u003c\/p\u003e \u003cp\u003eFillers 281\u003c\/p\u003e \u003cp\u003eProtocol for vascular occlusion from fillers 288\u003c\/p\u003e \u003cp\u003eVenous disease treatment 288\u003c\/p\u003e \u003cp\u003eVein treatment algorithm 288\u003c\/p\u003e \u003cp\u003eSclerotherapy 289\u003c\/p\u003e \u003cp\u003ePreparing dilution of sclerosants 290\u003c\/p\u003e \u003cp\u003eCEAP classification for venous disease 292\u003c\/p\u003e \u003cp\u003eVenous clinical severity score 292\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Drugs and Therapies 293\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMedication Quick Reference 295\u003c\/p\u003e \u003cp\u003eTopical steroids classified by strength 295\u003c\/p\u003e \u003cp\u003eNonsteroidals 297\u003c\/p\u003e \u003cp\u003eCommonly used drugs in dermatology 297\u003c\/p\u003e \u003cp\u003eSystemic Medications 302\u003c\/p\u003e \u003cp\u003eAntimalarials 302\u003c\/p\u003e \u003cp\u003eImmunosuppressive agents 303\u003c\/p\u003e \u003cp\u003eSystemic retinoids 306\u003c\/p\u003e \u003cp\u003eBiologics 307\u003c\/p\u003e \u003cp\u003eGeneral Reference 310\u003c\/p\u003e \u003cp\u003eMetric measurements 310\u003c\/p\u003e \u003cp\u003eDose calculations 310\u003c\/p\u003e \u003cp\u003eTopical medication dispensing and absorption 310\u003c\/p\u003e \u003cp\u003eCorticosteroid Dosage Equivalence 311\u003c\/p\u003e \u003cp\u003eAcne – Topical 311\u003c\/p\u003e \u003cp\u003eAntibiotics\/antimicrobial 311\u003c\/p\u003e \u003cp\u003eKeratolytics 312\u003c\/p\u003e \u003cp\u003eRetinoids 313\u003c\/p\u003e \u003cp\u003eOthers 313\u003c\/p\u003e \u003cp\u003eAcne – Oral 314\u003c\/p\u003e \u003cp\u003eAntibiotics 314\u003c\/p\u003e \u003cp\u003eRetinoids 315\u003c\/p\u003e \u003cp\u003eOthers 315\u003c\/p\u003e \u003cp\u003eAnalgesics 315\u003c\/p\u003e \u003cp\u003eAnesthetics – topical (see also topical anesthetic pg. 235) 316\u003c\/p\u003e \u003cp\u003eAnesthetics – topical compounded 316\u003c\/p\u003e \u003cp\u003eAntibiotics 316\u003c\/p\u003e \u003cp\u003eTopical\/antiseptic 316\u003c\/p\u003e \u003cp\u003eSystemic 317\u003c\/p\u003e \u003cp\u003ePreoperative prophylaxis see pg. 230\u003c\/p\u003e \u003cp\u003ePostoperative skin infection 319\u003c\/p\u003e \u003cp\u003eSensitivity 321\u003c\/p\u003e \u003cp\u003eRegimens 322\u003c\/p\u003e \u003cp\u003eSTDs 323\u003c\/p\u003e \u003cp\u003eAntifungals 324\u003c\/p\u003e \u003cp\u003eTopical 324\u003c\/p\u003e \u003cp\u003eOral 325\u003c\/p\u003e \u003cp\u003eAntifungal regimens 327\u003c\/p\u003e \u003cp\u003eCandidal infection 327\u003c\/p\u003e \u003cp\u003ePityrosporum folliculitis 327\u003c\/p\u003e \u003cp\u003eOnychomycosis 327\u003c\/p\u003e \u003cp\u003eTinea versicolor (\u003ci\u003eMalassezia\u003c\/i\u003e) 328\u003c\/p\u003e \u003cp\u003eTinea capitis 328\u003c\/p\u003e \u003cp\u003eTinea corporis 328\u003c\/p\u003e \u003cp\u003eTinea pedis 329\u003c\/p\u003e \u003cp\u003eAntiparasitics 330\u003c\/p\u003e \u003cp\u003eScabies 330\u003c\/p\u003e \u003cp\u003eLice 330\u003c\/p\u003e \u003cp\u003eAntivirals 331\u003c\/p\u003e \u003cp\u003eHSV 331\u003c\/p\u003e \u003cp\u003eHerpes zoster\/VZV 333\u003c\/p\u003e \u003cp\u003eGenital warts 333\u003c\/p\u003e \u003cp\u003eVerruca vulgaris 334\u003c\/p\u003e \u003cp\u003eMolluscum 334\u003c\/p\u003e \u003cp\u003eAntihistamines 334\u003c\/p\u003e \u003cp\u003eSedating 335\u003c\/p\u003e \u003cp\u003eNonsedating 335\u003c\/p\u003e \u003cp\u003eH2‐blockers 335\u003c\/p\u003e \u003cp\u003eAntipruritic 336\u003c\/p\u003e \u003cp\u003eTopical 336\u003c\/p\u003e \u003cp\u003eOral 336\u003c\/p\u003e \u003cp\u003eAnxiolytics\/Sedation 338\u003c\/p\u003e \u003cp\u003eBenzodiazepines 338\u003c\/p\u003e \u003cp\u003eAntihistamines 339\u003c\/p\u003e \u003cp\u003eBleaching Agents\/Depigmenting Agents 340\u003c\/p\u003e \u003cp\u003eHair 341\u003c\/p\u003e \u003cp\u003eAlopecia – androgenic 341\u003c\/p\u003e \u003cp\u003eAlopecia – areata 341\u003c\/p\u003e \u003cp\u003eHypertrichosis 342\u003c\/p\u003e \u003cp\u003eHypotrichosis – eyelash 342\u003c\/p\u003e \u003cp\u003eHyperhidrosis 342\u003c\/p\u003e \u003cp\u003ePsoriasis 343\u003c\/p\u003e \u003cp\u003eTopical agents 343\u003c\/p\u003e \u003cp\u003eTar 343\u003c\/p\u003e \u003cp\u003eAnthralin\/dithranol 343\u003c\/p\u003e \u003cp\u003eSystemic agents 343 (see also Systemic Medications pg. 306)\u003c\/p\u003e \u003cp\u003eRosacea 344\u003c\/p\u003e \u003cp\u003eAntibiotics\/antimicrobial – topical 344\u003c\/p\u003e \u003cp\u003eKeratolytics 344\u003c\/p\u003e \u003cp\u003eVasoconstrictor 344\u003c\/p\u003e \u003cp\u003eOther 344\u003c\/p\u003e \u003cp\u003eAntibiotics – systemic 344\u003c\/p\u003e \u003cp\u003eSeborrheic Dermatitis 345\u003c\/p\u003e \u003cp\u003eSkin Cancer – Topical and Oral Chemotherapy 345\u003c\/p\u003e \u003cp\u003eActinic keratoses (AK) 345\u003c\/p\u003e \u003cp\u003eBasal cell carcinoma (BCC) 346\u003c\/p\u003e \u003cp\u003eCTCL 346\u003c\/p\u003e \u003cp\u003eMelanoma 347\u003c\/p\u003e \u003cp\u003eVasoactive\/Antiplatelet Agents 347\u003c\/p\u003e \u003cp\u003eVitamins\/Nutritional Supplements 348\u003c\/p\u003e \u003cp\u003eWound Care 348\u003c\/p\u003e \u003cp\u003eMiscellaneous Meds 348\u003c\/p\u003e \u003cp\u003eCytochrome P‐450 interactions 349\u003c\/p\u003e \u003cp\u003ePregnancy Categories of Commonly Used Dermatologic Agents 350\u003c\/p\u003e \u003cp\u003eCommon Dermatologic Drugs and Teratogenic Effects 351\u003c\/p\u003e \u003cp\u003eDermatologic Drugs Reportedly Associated with Contraceptive Failure 352\u003c\/p\u003e \u003cp\u003eDrug Eruptions 352\u003c\/p\u003e \u003cp\u003eChemotherapeutic Agents and Skin Changes 355\u003c\/p\u003e \u003cp\u003eAntidote to extravasation of chemotherapeutic agents 358\u003c\/p\u003e \u003cp\u003eUV Light Treatment 359\u003c\/p\u003e \u003cp\u003eUVA\/UVB dosing 359\u003c\/p\u003e \u003cp\u003eNBUVB dosing 359\u003c\/p\u003e \u003cp\u003ePUVA 359\u003c\/p\u003e \u003cp\u003eToxic Epidermal Necrolysis (TEN) Protocol 361\u003c\/p\u003e \u003cp\u003eDiagnosis of TEN 361\u003c\/p\u003e \u003cp\u003eTriage algorithm for TEN patients 362\u003c\/p\u003e \u003cp\u003eTreatment for all TEN patients 363\u003c\/p\u003e \u003cp\u003eAppendix I American Burn Assocation Burn Center Referral Criteria 364\u003c\/p\u003e \u003cp\u003eAppendix SCORTEN Score 365\u003c\/p\u003e \u003cp\u003eAppendix III IVIg 365\u003c\/p\u003e \u003cp\u003eAppendix IV Further Reading for TEN\/SJS 366\u003c\/p\u003e \u003cp\u003eIndex 367\u003c\/p\u003e \u003cp\u003eColor plate section can be found facing page 208\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49406865506647,"sku":"9781118408544","price":46.95,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118408544.jpg?v=1730497381","url":"https:\/\/bookcurl.com\/products\/handbook-of-dermatology-9781118408544","provider":"Book Curl","version":"1.0","type":"link"}